Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
9.91
-0.03 (-0.30%)
At close: Jun 27, 2025, 4:00 PM
9.50
-0.41 (-4.14%)
After-hours: Jun 27, 2025, 7:31 PM EDT
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $68.16M in the quarter ending March 31, 2025, with 34.21% growth. This brings the company's revenue in the last twelve months to $294.62M, up 24.76% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$294.62M
Revenue Growth
+24.76%
P/S Ratio
4.50
Revenue / Employee
$727,457
Employees
405
Market Cap
1.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
| Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
| Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
| Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
| Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
DVAX News
- 16 days ago - Dynavax elects all four of its nominees after Deep Track proxy fight - Reuters
- 16 days ago - Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting - PRNewsWire
- 19 days ago - Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom - Business Wire
- 19 days ago - Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting - PRNewsWire
- 23 days ago - Dynavax Comments on Glass Lewis Recommendation - PRNewsWire
- 24 days ago - Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies - Business Wire
- 4 weeks ago - Dynavax to Present at William Blair's 45th Annual Growth Stock Conference - PRNewsWire
- 5 weeks ago - Deep Track Capital Comments on ISS Recommendation - Business Wire